	US 12,144,849 B2
	Composition comprising highly-concentrated Alpha1 proteinase inhibitor and method for obtaining thereof
James Rebbeor, Garner, NC (US); Charles Miller, Apex, NC (US); Anthony Klos, Raleigh, NC (US); Eric Allgaier, Wake Forest, NC (US); Thomas P. Zimmerman, Raleigh, NC (US); Kevin Wee, Wake Forest, NC (US); Michelle StPeter, Graner, NC (US); and Kelly Glancy, Holly Springs, NC (US)
Assigned to GRIFOLS WORLDWIDE OPERATIONS LIMITED, Dublin (IE)
Filed by GRIFOLS WORLDWIDE OPERATIONS LIMITED, Dublin (DE)
Filed on May 12, 2023, as Appl. No. 18/316,850.
Application 18/316,850 is a continuation of application No. 17/448,509, filed on Sep. 22, 2021, granted, now 11,701,412.
Application 17/448,509 is a continuation of application No. 16/529,686, filed on Aug. 1, 2019, granted, now 11,253,578, issued on Feb. 22, 2022.
Claims priority of provisional application 62/713,673, filed on Aug. 2, 2018.
Prior Publication US 2023/0277636 A1, Sep. 7, 2023
Int. Cl. A61K 38/55 (2006.01); A61K 47/12 (2006.01); A61K 47/26 (2006.01); A61K 47/30 (2006.01)

CPC A61K 38/55 (2013.01) [A61K 47/12 (2013.01); A61K 47/26 (2013.01); A61K 47/30 (2013.01)]

17 Claims

1. A composition comprising Alpha1-Proteinase Inhibitor (A1PI) in an aqueous solution and one or more uncharged excipients that maintain pH to around 6.6 to 7.4 without the use of buffers such that the composition is buffer-free, wherein the concentration of A1PI is greater than 100 mg/ml.